Abbott Laboratories

2004 Fact Book

Abbott Laboratories
Founded in 1888 by Dr. Wallace Calvin Abbott,
a Chicago physician, Abbott Laboratories is a
broad-based health care company that discovers,
develops, manufactures and markets products
and services that span the continuum of care
from prevention and diagnosis to treatment
and cure. Abbotts principal businesses include
pharmaceuticals and medical products, including
nutritionals, devices and diagnostics.
Headquartered in north suburban Chicago,
Abbott serves customers in more than 130
countries, with a staff of 55,000-plus*at more
than 120 manufacturing, distribution, research
and development, and other locations.
* Prior to its spin off of Hospira on May 3, 2004, Abbott
employed more than 70,000 people worldwide.
Contents
2
4
5
6
10
12
13
13
14
14
16
17
18
19
20
24
26
28
28
29

Financial Highlights
Market-Leading Positions and Abbotts Leading Brands
Rankings
Pharmaceutical Products
Medical Products
Medical Products Diagnostics
Medical Products Abbott Molecular Diagnostics
Medical Products Abbott Diabetes Care
Medical Products Point-of-Care
Medical Products Nutritionals
Medical Products Abbott Vascular Devices
Medical Products Spinal Concepts
Medical Products Animal Health
TAP Pharmaceutical Products
Abbotts Commitment to Global Citizenship
History
Six-Year Financial Summary
Plant Locations
Directors
Senior Management and Corporate Officers

Abbott is focused
on advancing patient
care by developing
innovative solutions
in pharmaceuticals,
diagnostics,
medical devices
and nutritionals.

Financial Highlights
In 2003, Abbott reported sales and net earnings
of $19.7 billion and $3.5 billion, respectively. Abbott
also recorded its 320th consecutive quarterly dividend
to be paid to shareholders since 1924. In addition,
2003 marked the 31st straight year Abbotts dividends
have increased. The companys Pharmaceutical
Products Group which includes U.S. pharmaceuticals,
specialty products and international sales of pharmaceutical, nutritional and hospital products generated
sales of more than $11 billion. The Medical Products
Group which includes worldwide diagnostics, U.S.
hospital products and U.S. nutritionals generated
more than $8 billion in sales.

2003 Sales by Division

Total: $19.7 billion
Pharmaceutical
Products Group
$11.4 billion

Medical
Products Group
$8.3 billion

U.S. Hospital Products

U.S. Pharmaceuticals

U.S. Nutritionals

Worldwide Diagnostics

International
Other

Abbotts leadership positions in several multibilliondollar businesses provide a unique balance of revenue
growth opportunities and cash flow sources that
allow the company to invest in its future. To further
strengthen its business and sustain its success, Abbott
invested more than $1.7 billion in R&D in 2003.

1.0

0.8

During 2003, Abbotts operating cash flow was $3.7

billion. The company plans to continue to use its
strong cash flow to support its dividend policy, repay
debt and buy back stock under the companys share
repurchase program.

0.6

0.4

0.2

20

2.0

15

1.5

(dollars in billions)
.

(dollars in billions)

2003: $7.9 $11.8 $19.7

2002: 6.9 10.8 17.7
2001: 6.2 10.1 16.3
8.6 13.7
2000: 5.1
8.1 13.2
1999: 5.1

1.0

..

2003: $0.98
2002: 0.94
2001: 0.84
2000: 0.76
1999: 0.68

Research and development

Net sales worldwide

10

Cash dividends
declared per share

0.5

2003: $1.7
2002: 1.6
2001: 1.6
2000: 1.4
1999: 1.2

Market-Leading Positions
and Abbotts Leading Brands

Ensure, Glucerna, ZonePerfect
-
Biaxin / Biaxin XL / Klacid / Klaricid
Omnicef

Flomax

AbbottPrism system
Viral screening reagents

TriCor

MediSense Precision Xtra
MediSense Precision PCx
TheraSense FreeStyle
TheraSense FreeStyle Flash

Cell-Dyn systems and reagents

AxSym system and reagents

Humira

Rankings
Abbott is ranked among the top
companies in the world for financial
strength and workplace excellence by
leading national publications, including:
Fortune
Ranked 96th on the Fortune 500 list of the largest
U.S.-based corporations (ranked by 2003 revenue).
Recognized as one of the Most Admired Companies
in the pharmaceutical sector every year since 1984.
Ranked among the 50 Best Companies for Minorities
in the United States for the sixth consecutive year.

Forbes
Ranked 121 on the Forbes 2000 list.
(ranked by sales, profits, assets and market value).

Health
Selected as one of the 10 Best Companies for Women.

Money
Named one of Americas Best Stocks.

Similac Advance
Isomil Advance

Working Mother

Ultane / Sevorane

R&D Directions

Named one of the 10 Best Employers for Mothers.

Named one of the 10 Best Pipelines.

Depakote / Depakote ER

Kaletra, Norvir

Zemplar

Synthroid

Perclose products
4

Pharmaceutical
Products Group

Abbotts Pharmaceutical Products

Group aims to create a top-tier global
pharmaceutical business one that is
dedicated to discovering, developing and
marketing breakthrough drugs that
improve patient health. The groups
primary focus is on translating innovative science into effective medicine.

Pharmaceutical Products
Abbott sells pharmaceutical products in key therapeutic areas through
several divisions, including the Pharmaceutical Products Division, the
Ross Products Division, and Abbott International.
AIDS/Anti-virals. Drugs to treat HIV/AIDS.
Kaletra (lopinavir/ritonavir)

Advanced-generation protease inhibitor for the

treatment of HIV/AIDS.

Norvir (ritonavir)

Protease inhibitor for the treatment of HIV/AIDS.

Anti-infectives. Antibiotics for the treatment of respiratory infections

and skin infections.
Biaxin, Klacid, Klaricid
(clarithromycin)
Biaxin XL, Klaricid OD
(extended-release formulation)

Macrolide antibiotic for the treatment of upper and

lower respiratory tract infections, and skin and skin
structure infections; treatment and prevention of
Mycobacterium avium complex (MAC); and
eradication of the ulcer-causing bacterium H. pylori.

Erythromycin, PCE

Generic and polymer-coated antibiotic.

Omnicef (cefdinir)

An oral cephalosporin antibiotic for the treatment

of a wide range of infections, including chronic
bronchitis, ear infections, pneumonia, sinus
infections, and throat and tonsil infections.

Cardiovascular. Includes anti-hypertensive medicines for reducing

high blood pressure and medicine for reducing high cholesterol
and triglycerides.
Blopress, Tiadyl (candesartan) Angiotension-2 antagonist for hypertension.
Mavik (trandolapril) and
Long-acting angiotensin-converting enzyme (ACE)
Tarka (trandolapril/verapamil) inhibitor, and combination of ACE inhibitor and
calcium channel blocker, respectively.
Micardis (telmisartan)

Angiotension-2 antagonist for hypertension.*

TriCor (fenofibrate)

Cholesterol- and triglyceride-reducing agent.

Abbokinase (urokinase)

Injectable pharmaceutical agent that dissolves blood

clots in the treatment of pulmonary embolism.

Gastrointestinal. Drugs to treat diseases of the GI track.

Prevacid, Ogastro
(lansoprazole)

Proton pump inhibitor for gastroesophageal reflux

disease (GERD), ulcers and other diseases
characterized by excess stomach acid. (Marketed in
the United States by TAP Pharmaceutical Products Inc.)

Immunology. Drugs used to treat diseases of the immune system,

including rheumatoid arthritis.
Humira (adalimumab)

Fully human monoclonal antibody for

rheumatoid arthritis.

Metabolic Disease. Includes medicines for the management of obesity

and the treatment of thyroid disease.
Meridia, Reductil (sibutramine Serotonin and norepinephrine re-uptake inhibitor
hydrochloride monohydrate) (SNRI) for the management of obesity.
Synthroid
(levothyroxine sodium)

Depakote, Epival, Valcote

(divalproex sodium)
Depakote ER
(extended-release
formulation)

Anti-epileptic agent also used for the treatment of

the manic phase of bipolar disorder and for the
prevention of migraine headaches. Extended-release,
once-daily formulation for the treatment of
epilepsy (adult/pediatric) and the prevention of
migraine headaches.

Mobic (meloxicam)

Preferential COX inhibitor to treat pain from

rheumatoid arthritis and osteoarthritis.**

Dilaudid (hydromorphone
hydrochloride)

Analgesic for moderate-to-severe pain.

Vicodin (hydrocodone/
acetaminophen)

Analgesic for moderate-to-severe pain.

Vicoprofen (hydrocodone/
ibuprofen)

Analgesic for acute pain.

Pediatric and Neonatal Pharmaceuticals. Drugs for serious

respiratory conditions.
Survanta (beractant)

Lung surfactant used to treat and prevent respiratory

distress syndrome (RDS) in premature newborns.

Synagis (palivizumab)

Monoclonal antibody for the prevention of serious

respiratory syncytial virus (RSV) infection.

Perioperative and Intensive Care Pharmaceuticals. Provides injectable

inhalation anesthetic agents, neuromuscular blockers, sedatives and
other analgesic pain therapies.
Mivacron (mivacurium Cl)
Nimbex (cisatracurium besylate)
Nuromax (doxacurium Cl)
and Tracrium
(atracurium besylate)

Neuromuscular blockers used as adjuncts to general

anesthesia. These products can be used prior to
surgery to ease endotracheal intubation and during
surgery to facilitate skeletal muscle relaxation and
mechanical ventilation.

Sevorane, Ultane
(sevoflurane)

Unique inhalation anesthetic for both inpatient and

outpatient procedures, for adult and pediatric use.

Simdax (levosimendan)

Injectable for acute congestive heart failure.

(Marketed outside the United States.)

Renal Care Pharmaceuticals. Injectable vitamin D agent developed to

treat patients with complications of end-stage renal disease.
Zemplar
(paricalcitol injection)

Next-generation therapy for the prevention and

treatment of secondary hyperparathyroidism
associated with chronic renal failure.

Urology and Reproductive Health. Includes medicines for benign

prostatic hyperplasia (BPH), advanced prostate cancer, endometriosis,
anemia associated with uterine fibroids, and central precocious puberty.
Flomax (tamsulosin HCl)

Alpha blocker for the treatment of BPH.*

Hytrin (terazosin HCl)

Once-a-day alpha blocker for hypertension and

symptoms of BPH.

Lupron, Lucrin
(leuprolide acetate)

Synthetic hormone for the treatment of advanced

prostate cancer, endometriosis, anemia caused by
fibroid tumors (in combination with iron), and
central precocious puberty. (Marketed in the United
States by TAP Pharmaceutical Products Inc.)

Synthetic thyroid hormone for the treatment of

hypothyroidism.

* Marketed in the United States through an alliance with Boehringer Ingelheim Pharmaceuticals.
8

Neuroscience and Pain. Drugs to treat neurological conditions, as

well as medications for pain management.

** Marketed in the United States and Latin America through an alliance with
Boehringer Ingelheim Pharmaceuticals.

Medical
Products Group

10

Abbotts Medical Products Group has

built leading businesses in diagnostic
testing and instrumentation;
hospital-based devices; and nutritional
products for children and adults.
The group is committed to developing
innovative, highly differentiated
products for patients and consumers.

11

Medical Products Diagnostics

Medical Products Abbott Molecular Diagnostics

The Medical Products Group offers a broad range of innovative

instruments and tests across key segments in the global diagnostics
market, including hospitals, reference laboratories, blood banks,
physicians offices, and clinics. Abbott Diagnostics provides a broad
portfolio of products to serve clinical laboratory customers worldwide.

Abbott Molecular Diagnostics technology provides physicians with

critical information based on the detection of subtle changes in
patients genes and chromosomes allowing for earlier detection,
selection of appropriate therapies and monitoring of diseaseprogression. Includes instruments and reagents used to conduct
sophisticated analysis of patient DNA and RNA. In 2002, Abbott
formed an alliance with Celera Diagnostics to develop and market
novel molecular diagnostic products.

Immunoassay and Clinical Chemistry. Includes systems and assays to

measure a variety of analytes found in the blood and to diagnose and
monitor diseases and therapies. Also includes blood screening instrumentation and assays used to ensure the safety of the blood supply.
AbbottPrism

Fully automated analyzer specifically designed for

high-volume blood centers and blood banks to
screen donated blood for multiple viral assays. Menu
includes HIV, hepatitis and HTLV assays. (Marketed
outside the United States.)

Aeroset and c8000

High- and medium-volume clinical chemistry

analyzers with broad testing menus to facilitate
routine and specialty testing.

Architect i2000, i2000SR,

ci8200 and i4000

Modular analyzers that provide immunoassay and

clinical chemistry results. Menu includes tests for
cancer, thyroid, fertility, anemia and pregnancy.

AxSym

Automated immunoassay analyzer with continuous

access and STAT capabilities. Menu includes tests for
cancer, cardiovascular, drugs of abuse, fertility,
pregnancy and thyroid.

IMx

Automated benchtop analyzer for immunoassay

testing. Menu includes tests for thyroid, cancer,
fertility and cardiovascular markers.

TDx and TDx Flx

Automated benchtop analyzers for monitoring

therapeutic drug levels. Menu includes theophylline,
vancomycin, drugs of abuse and thyroid tests.

Determine

Self-contained test strips for use by a wide range of

health care professionals. Menu includes tests for
HIV, hepatitis and syphilis. (Marketed outside the
United States.)

OraQuick

Rapid, simple, whole-blood test for HIV. (Marketed

in the United States in collaboration with OraSure
Technologies, Inc.)

Hematology. Abbott develops, manufactures and markets Cell-Dyn

hematology systems used to perform sophisticated blood cell analysis.
Cell-Dyn 4000, 3700,
3200 and 1800

12

A complete line of highly automated hematology

analyzers to meet the testing needs of any laboratory,
whether high or low volume.

LCx

Easy-to-use benchtop analyzer for detecting viruses

such as HIV at levels undetectable by other
technologies. (Marketed outside the United States.)

PathVysion HER-2
DNA Probe Kit

DNA-based tests that detect the HER-2/neu gene in

breast cancer patients. Patients testing positive for
this gene are candidates for treatment with
Herceptin, a targeted monoclonal treatment.

UroVysion

A DNA-based test for monitoring recurrence of

bladder cancer. Provides early detection through the
identification of genetic changes.

ViroSeq HIV-1
Genotyping System

A sequencing-based testing method for accurate

identification of known drug-resistant HIV-1
mutations. (Marketed by Abbott as part of the
Celera Diagnostics alliance.)

Medical Products Abbott Diabetes Care

Abbott Diabetes Care is committed to providing innovative handheld systems to assist patients and health professionals in the
management of diabetes. Includes hand-held glucose monitors and
biosensor-based strips that offer patients convenient, accurate
and fast results.
Precision PCx

A hand-held, point-of-care blood glucose testing

system developed to meet the unique testing and data
management needs of the hospital. Version 2.2.1
offers improved data communication speeds and an
end-fill strip technology.

Precision Q.I.D.

A small, lightweight glucose monitor designed not to

start until a sufficient blood sample is detected.

Precision Xtra and

Precision Xtra Luminous

First hand-held monitor to offer ketone testing

capabilities; the Luminous monitor offers added
lighting features.

FreeStyle

A leading blood glucose monitoring system, which

allows patients reduced pain through alternate-site
testing and a small (0.3 microliter) sample size.

FreeStyle Flash

The worlds smallest blood glucose monitor that

returns an accurate reading in just seven seconds
with a 0.3 microliter sample. The Flash monitor
offers unique lighting features.

FreeStyle Tracker

Combines a blood glucose meter, diabetes manager,

and personal digital assistant (PDA) all in one
compact device.

13

Medical Products Point-of-Care

Abbotts Point-of-Care business provides health care professionals
immediate access to accurate, critical diagnostic test results at the
point of patient care.
i-STAT

A market-leading system comprising a hand-held

analyzer and a number of single-use disposable
cartridges that include panels of tests for electrolytes,
metabolytes, blood gases, coagulation, and cardiac
markers that deliver results in a few minutes at the
patients bedside.

Pediatric Nutritionals. Abbott develops products that support the

growth and development of infants and children, and makes these
products available in innovative, consumer-friendly packaging.
Specialty formulations include products for premature and lowbirthweight infants; products for infants and children with special
tolerance or nutritional needs; hypoallergenic formulations for infants
and children with multiple food allergies or severe gastrointestinal
impairment; and a line of products for infants and children with
metabolic diseases.
Alimentum Advance

Formula for infants with food allergies or colic due

to protein sensitivity. Alimentum Advance is
supplemented with DHA and ARA, two fatty acids
found in breast milk that are important for brain and
visual development.

EleCare

Nutritional formula for infants and children with

multiple food allergies or severe gastrointestinal
impairment.

Formance

Nutritional supplement for expectant mothers.

Gain and Grow

A line of follow-on formulas for children 6 months

to 18 months (Gain) and up to 7 years (Grow).

Isomil Brand

A broad line of soy-based formula for infants with

common feeding problems. Isomil Advance with Iron
is supplemented with DHA and ARA, two fatty acids
found in breast milk that are important for brain
and visual development, Isomil DF (for dietary
management of diarrhea for infants 6 months or
older), and Isomil 2 Advance (follow-on formula for
babies and toddlers of ages 9 months to 24 months).

Similac Special
Care Advance and
Similac NeoSure Advance

Specialized infant formulas designed for premature

and low-birth-weight babies. Special Care Advance
and NeoSure Advance are supplemented with DHA
and ARA, two fatty acids found in breast milk that
are important for brain and visual development.

Pedialyte

Oral electrolyte maintenance solution to help prevent

dehydration by quickly replacing fluids and
electrolytes lost during diarrhea and vomiting. Also
available as Pedialyte Freezer Pops and Pedialyte Singles.

PediaSure

Complete, balanced nutritional formula in a variety

of flavors for children ages 1 to 10 years. Available
with fiber, as an oral supplement, and in a
tubefeeding formulation.

Similac Brand

A complete line of next-generation infant formulas

that have added nucleotides to help support immune
system development. Includes Similac Advance and
Similac Lactose Free Advance (an alternative to
standard milk-based formulas); supplemented with
DHA and ARA, two fatty acids found in breast milk
that are important for brain and visual development.
Similac 2 Advance is a follow-on formula for babies
and toddlers 9 months to 24 months also containing
DHA and ARA.

Medical Products Nutritionals

Abbotts Ross Products Division is a leader in providing trusted
pediatric nutritionals, adult nutritionals and related health care
products that advance peoples quality of life. Ross develops and
markets nutritional products for the United States, while Abbott
International markets these products outside the United States.
Adult Nutritionals. Abbott offers a broad selection of products that
provide complete, balanced nutrition for healthy adults, as well as
medical food products for people with special dietary needs due to
diabetes, cancer-induced weight loss, renal disease or respiratory
conditions. Abbott also offers medical nutritionals for patients needing
supplements or requiring tube feeding.
Companion, Embrace,
Flexiflo, Patrol and Quantum

Complete line of enteral feeding pumps, tubes

and devices.

Ensure

A broad line of leading adult nutritionals, providing

a source of complete, balanced nutrition. Ensure
liquid and bars are available in a variety of flavors
and specialized formulas. The product line includes
Ensure, Ensure Plus (a higher calorie concentration),
Ensure High Protein, Ensure Fiber with FOS, and
Ensure High Calcium.

Glucerna

The leading brand of specialized nutritional products

for patients with diabetes. Available as shakes, meal
bars, snack bars, and tube feeding formulations.
Glucerna Weight Loss Shake is the first weight loss
shake designed for people with diabetes.

Jevity

Fiber-fortified, high-protein liquid formula for both

short- and long-term tube feeding.

Nepro and Suplena

Specialized nutritional products for people with

kidney disease.

Optimental

A ready-to-feed elemental nutritional formula for

patients with malabsorptive conditions, such as
Crohns disease, metabolic stress, or acute trauma.

Osmolite

An isotonic, low-residue liquid formula providing

complete, balanced nutrition.

Oxepa and Pulmocare

Specialized nutritional products for patients with

respiratory conditions, including acute lung injury
(Oxepa) and pulmonary disease (Pulmocare).

ProSure

Specialized nutrition and energy product clinically

shown to promote weight gain, help build muscle
and improve the quality of life for people with
cancer-induced weight loss.

ZonePerfect

A leading brand of convenient, portable nutritional

products developed to satisfy hunger through a
unique balance of carbohydrates, protein, and fat.
Available as bars, shakes, and prepared meals.

14

Similac Human Milk Fortifier A nutritional supplement to add to preterm human

milk for low-birth-weight infants.

15

Medical Products Abbott Vascular Devices

Medical Products Spinal Concepts

Abbott Vascular Devices markets a portfolio of coronary and

endovascular technologies, vessel closure devices, and pharmaceuticals
used in the treatment of cardiovascular conditions.

Spinal Concepts, an innovative leader in spinal implant technology,

offers surgeons a unique product portfolio with technologically
advanced devices for the cervical, thoracic and lumbar spine.

Asahi Guidewires

A full product line of PTCA guidewires that facilitate

access to diseased vessels and deliver interventional
tools and devices.

BiodivYsio

A line of polymer-coated stents. Includes the SV stent

designed for small vessels and the OC stent, which
offers increased flexibility.

Chito-Seal

A topical hemostasis pad (patch) used to expedite

clot formation and to accelerate hemostasis after
vessel closure procedures.

Dexamet SV

Drug-eluting stent that combines dexamethasone

with an innovative coating designed to mimic
the bodys chemistry. (Marketed outside the
United States.)

EmboShield

EmboShield Cerebral
Protection Device and
Xact Stent System

A device with a differentiated distal protection

filter used to capture emboli dislodged during
coronary stenting procedures. (Marketed outside
the United States.)
A peripheral embolic protection device with a
differentiated distal protection filter and a carotid
stent. The Emboshield device is used to capture
emboli dislodged during carotid stenting with the
Xact stent. (Marketed outside the United States.)

Biologics. Includes allograft and synthetic bone void filler to provide

platform for fusion and bone regeneration.
Cerasorb

A resorbable, synthetic bone void filler that promotes

bone remodeling over time.

Natural Selection

A line of allograft (donor bone) spacers used to

restore height between the vertebral bodies of the
cervical and lumbar spine.

Cervical Systems. Includes a full line of anterior and posterior

cervical options.
SC-AcuFix

A line of anterior cervical plates that facilitates fusion

of cervical vertebrae. Includes the SecureRing
mechanism to prevent bone screw disengagement.

Ant-Cer

Used for dynamic stabilization of the cervical spine.

CFix

Cable fixation system that allows for easy

retightening to apply a precise amount of tension
in the spine.

OctaFix

Internal fixation system for immediate stability

within the occipital cervical fixation junction.

Nex-Link

A versatile technology used to stabilize the posterior

cervical and upper thoracic spine.

Fox PTA Catheter

A balloon catheter system that is designed to dilate

narrowed peripheral arteries. A low profile, tapered
tip, and hydrophilic coating provide for excellent
deliverability to the lesion.

Jostent GraftMaster

A unique and innovative covered stent graft marketed

in the United States as a humanitarian device.*

Jography

A portfolio of catheters with specialized tips and

extra large lumens designed to optimize angiographic
results during diagnostic procedures.

Harmony

A common platform of disc preparation instruments

used with all Spinal Concepts posterior lumbar
interbody fusion spacers.

Perclose A-T

Suture-mediated vessel closure device that features

automated knot-tying to expedite the closure process.

Cadence Ti
Cadence Vue

A device that is implanted in the

thoracolumbar spine using a posterier approach.

The Closer S (with snared

knot pusher, clincher and
suture trimmer)

Minimally invasive devices that automate the surgical

closure of blood vessels.

Fortitude Ti
Fortitude Vue

A device that is implanted through an

anterior approach.

Xceed

A Nitinol self-expanding biliary stent system with a

proprietary delivery system that offers its users
placement accuracy with single-handed deployment.

TraXis Ti
TraXis Vue

An alloy spacer used with a transforamenal

(oblique) approach to restore height in the vertebral
bodies of the thoracolumbar spine. (A lumbar
interbody fusion spacer outside the United States.)

Xpert

A self-expanding biliary stent system that offers the

lowest profile of any self-expanding biliary stent on
the market.

InFix

A modular titanium device that is implanted through

an anterior approach. The device is novel in that it is
assembled within the disc space, can be designed
to approximate the specific patients anatomy, and is
able to load the internal graft material while
protecting it from excessive strain.

*Humanitarian Device. Authorized by U.S. federal law for the use in the treatment of free perforations,
defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein
bypass grafts >2.75 mm in diameter. The effectiveness of this device for this use has not been demonstrated.

16

Interbody Systems. Includes anterior column spacers that can be

inserted in a variety of anterior or posterior approaches.

17

Thoracolumbar Systems. Includes pedicle screw fixation options to

meet various surgical philosophies.
BacFix

Thoracolumbar screw, hook and rod system utilizing

a simple and efficient taper lock technology to
stabilize the spine.

InCompass

Thoracolumbar spinal fixation system designed to

provide superior fixation with the benefits of
reduced implant volume, lower profile and easier
construct assembly.

Access Dilation Port

Series of dilators that gently pushes aside soft

tissue for a minimally invasive approach to
microdiscectomy.

PathFinder

A minimally invasive pedicle screw system that may

reduce blood loss and recovery time.

SpeedLink

Easy to use, low profile and completely adjustable

transverse connector that precisely attaches to rods
using an integral cam locking mechanism.

Bone Plates. Provides a wide variety of bone plates to stabilize small

bones of the hand and foot.
Unison

A line of plates that offers internal fixation for

immediate stability to achieve bone fusion.

Medical Products Animal Health

Abbotts Animal Health Division is a leader in perioperative health
care for the veterinary market. Products include anesthetic and wound
care products; nutritionals; a complete line for I.V. fluid therapy; and
other veterinary critical care products.
PropoFlo (propofol)

Intravenous anesthetic for induction and maintenance.

SevoFlo (sevoflurane)

Inhalant anesthetic, which provides veterinarians

rapid induction of anesthesia and excellent control
during the maintenance phase of anesthesia.

CliniCare

A ready-to-feed liquid nutritional supplement for

cats and dogs. Appropriate for tube, syringe and
bowl feeding methods.

HemaBlock

Hemostatic agent (microporous polysaccharide

beads) made from natural starches that typically clots
within 30 seconds and is eventually broken down by
body enzymes within seven days. It can be used in
many bleeding sites, including dental procedures
and tumor biopsies.

Nexaband S/C Adhesive

A medical-grade tissue adhesive that can be used

instead of sutures and staples to close incisions.
It provides a flexible barrier during healing and eases
away naturally within seven to 10 days.

18

TAP Pharmaceutical Products

TAP Pharmaceutical Products Inc. was
established in 1977 as a joint venture between
Abbott and Takeda Chemical Industries, Ltd. of
Japan. The company is unique in that it does not
have its own internal discovery or manufacturing
organizations. Instead, the company partners
with outside organizations to develop new
compounds. The company applies its expertise
in research and development, quality assurance,
and sales and marketing to help bring to market
leading products that improve peoples lives.
TAP focuses its drug development in three major
areas: gastroenterology, urology and womens
health. The company develops and markets
pharmaceuticals for sale in the United States and
Canada, and licenses international rights for
some of these products to Abbott International.
TAPs current products include Prevacid
(lansoprazole), a proton pump inhibitor for
gastroesophageal reflux disease (GERD), ulcers
and other acid-related disorders; and Lupron
(leuprolide acetate) for the treatment of advanced
prostate cancer, endometriosis, anemia caused
by fibroid tumors (in combination with iron),
and central precocious puberty. In 2003, both
products were leading drugs in their classes and
among the top-selling drugs overall in the
United States, with combined 2003 sales of
nearly $4 billion.

19

Abbotts Commitment to
Global Citizenship
Global citizenship reflects how Abbott
advances its business objectives;
engages its stakeholders; implements
its policies; applies its social investment
and philanthropy; and exercises its
influence to make a productive
contribution to society. Being socially
responsible extends to all aspects of
how we operate from ethics and
compliance, product quality, diversity
in the workplace, environment, health
and safety, to employee volunteerism.
Our programs reflect an engagement
and partnership with many organizations in the pursuit of sustainable
solutions to challenges facing the global
community. For more information,
see www.abbott.com/citizenship.

20

21

Abbotts Commitment to Global Citizenship

Global Care Initiatives

Corporate Governance
Abbott has a long tradition of strong financial controls and corporate governance. Ten of the 13 members on the board of directors
are independent directors. The chairs and members of the boards
Audit Committee, Compensation Committee, Public Policy
Committee, and Nominations and Governance Committee are
independent directors.

Abbott Access
Abbott provides HIV medicines at a loss and rapid HIV tests at
no profit to the company to developing countries hardest hit by
HIV/AIDS. For more information, see www.accesstohivcare.org.

Ethics and Compliance

Ethical leadership is part of Abbotts management culture. The
companys Code of Business Conduct guides employees on ethical
and legal issues, and the Office of Ethics and Compliance provides
employees with a number of resources, including an Ethics and
Compliance Helpline, division level compliance staff, and extensive in-person and web-based training programs.

Determine HIV Rapid Test Donation Program

Abbott donates rapid HIV tests to programs working to
prevent mother-to-child transmission of HIV in 68 developing
countries. For more information, see www.pmtctdonations.org.
Step Forward for the worlds children
The Abbott Laboratories Fund, through the Step Forward
program, is improving the lives of orphans and vulnerable
children affected by HIV/AIDS in the developing world.
For more information, see www.stepforwardforchildren.org.

Diversity and Inclusiveness

Consistent with building a high performance organization, Abbott
works to create an inclusive work environment and an employee
population that reflects the diverse marketplace it serves. Diversity
and inclusiveness are reflected in our companys polices and practices, ranging from recruitment, professional development, flexible
work arrangements, to the advancement of women and minorities
in leadership positions.

Tanzania Care
Abbott and the Abbott Laboratories Fund are working with the
government of Tanzania to strengthen the countrys health care
infrastructure and systems to expand access to quality care for
people living with HIV/AIDS. For more information, see
www.tanzaniacare.org.

Environment, Health and Safety

Abbott has an established environment, health and safety policy
and management system to minimize the companys impact on
the environment and to create a safe workplace for our employees.
EHS programs address a number of areas, including conservation,
energy use, waste management, ergonomics, occupational health
and fleet safety.

U.S. Product Access Programs

Product Donations
Abbott works with a number of international agencies to deliver
pharmaceutical, nutritional, and hospital products in support of
medical missions, disaster relief efforts, and other humanitarian
programs around the world.

22

Patient Assistance Program

Abbott provides medicines free of charge to thousands of patients
who are uninsured, financially disadvantaged and ineligible for
publicly funded drug coverage.
Humira Medicare Assistance Program
Abbott provides Humira, its novel rheumatoid arthritis medicine,
at no cost to Medicare-eligible patients without prescription drug
coverage. For more information, see www.humira.com.
Together Rx Program
Founded by Abbott and six other major pharmaceutical companies, the Together Rx discount program offers qualified Medicare
patients discounts on more than 170 medicines. For more information, see www.together-rx.com.

23

History
A tradition of innovation
More than a century ago, 30-year-old Wallace C.
Abbott, M.D., began making a new form of
medicine. Using the active or alkaloid
part of a medicinal plant, he formed tiny pills,
called dosimetric granules, which provided a
measured amount of the drug. The demand for
these accurate granules soon far exceeded the
needs of his own practice. From a small
operation based above Dr. Abbotts pharmacy,
Abbott Laboratories has evolved into one of
the worlds leading health care companies.

1985

Abbott wins U.S. approval to market the worlds first diagnostic test for AIDS,
and launches ADD-Vantage, a unique I.V. drug-delivery system. TAP receives
approval for Lupron, a new therapy for prostate cancer.

1987

Hytrin (terazosin), a new cardiovascular drug for the treatment of

hypertension, receives FDA approval.

1988

Abbott celebrates its centennial. The IMx immunoassay system is introduced

and goes on to become one of the best-selling new products in Abbotts history.

1990

Biaxin, an important new macrolide antibiotic, is introduced.

1991

Several major products are introduced worldwide, including Survanta, for

the treatment of neonatal respiratory distress syndrome. Abbott enters the
hematology testing market with the acquisition of Sequoia-Turner Corp.

1993

Hytrin receives FDA clearance for use in treating symptoms of benign

prostatic hyperplasia, a condition of the prostate. Abbott launches
AxSym, a new, labor-saving diagnostic system.

1994

Abbott introduces sevoflurane, the first truly universal anesthetic, and

completes an agreement to cross-license LCR and PCR, two gene
amplification technologies.

1995

TAP receives approval for Prevacid, a proton pump inhibitor used in

treating ulcers. AbbottPrism, the first fully automated, high-volume

1888

Dr. Abbott begins producing dosimetric granules in his apartment on

1900

The business is officially incorporated in Illinois as the Abbott

treatment of HIV and AIDS. The company enters the glucose testing market

Alkaloidal Company.

with its acquisition of MediSense, Inc.

Chicagos North Side.

1915

The company changes its name to Abbott Laboratories.

1920

Dr. Abbott breaks ground for a new manufacturing facility in

blood analyzer, is introduced outside the United States.

1996

1997

1931

Abbott stock is listed on the Chicago Stock Exchange. The offering

of Similac infant formula in the United States.

1998

nutritionals for people with diabetes. Depakote surpasses lithium as the

Abbott establishes its first international affiliate in Montreal, Canada.

most-prescribed drug for treating mania. Abbott launches several

Abbott introduces the anesthetic agent Pentothal, developed by Abbott

pharmaceutical products, including Zemplar, TriCor and Synagis.

1999

scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they
are named to the U.S. Inventors Hall of Fame in 1986.
1941
1952

Perclose, Inc., a leading vascular closure devices company.

2000

1965
1973

including Kaletra (an advanced-generation protease inhibitor for the

treatment of HIV/AIDS), Biaxin XL (a once-daily version of its flagship

Erythrocin, a new antibiotic with good activity against gram-positive

antibiotic), and Depakote ER (for migraine prevention).

2001

1980
1983

BASF, including the global operations of Knoll Pharmaceuticals.

Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals.

In addition, Abbott acquires Vysis, Inc., a leading genomic disease

The company merges with M&R Dietetic Laboratories, of Columbus, Ohio,

management company.
2002

Abbott receives FDA approval for Humira (for rheumatoid arthritis),

which eventually becomes Abbotts Ross Products Division.

Synthroid (for hypothyroidism) and Abbokinase (for pulmonary embolism).

Abbott moves major operations to Abbott Park, a 420-acre site

The company launches Similac Advance, Isomil Advance and NeoSure Advance

southwest of its North Chicago headquarters.

infant formulas in the United States. Abbott acquires the cardiovascular stent

Abbott forms its diagnostics division to bring together all diagnostic

business of Biocompatibles International plc.

2003

Abbott launches three new immunodiagnostics systems on the Architect

adult medical nutritional.

platform. Abbott receives European regulatory approval for Humira.

TAP Pharmaceuticals, now known as TAP Pharmaceutical

Ross launches Glucerna Weight Loss Shake. The company launches the

Products Inc., is formed as a joint venture between Abbott and

MediSense Precision PCx 2.2.1 system worldwide. Abbott acquires JOMEDs

Takeda Chemical Industries, Ltd.

coronary and peripheral intervention business lines, Spinal Concepts, Inc.,

Abbott acquires Sorenson Research of Salt Lake City, Utah, which

ZonePerfect Nutritional Company, and Integrated Vascular Systems, Inc.

makes innovative medical disposables.

The company announces the spin-off of much of its core hospital products

In Japan, Abbott merges three facilities into one unified health care company
called Dainabot, K.K. Depakote, a new treatment for epilepsy, is approved
in the United States.

24

Abbott completes the acquisition of the pharmaceutical business of

Abbott enters a joint venture with Dainippon Pharmaceutical Co.,

products and services. The company also introduces Ensure, the first
1977

Abbott receives FDA approval for several new drugs or line extensions,

commercial production of penicillin.

Major plant expansions are completed in England, Italy and France.

1964

Abbott launches Architect, a next-generation diagnostic system, and acquires

Abbott is one of the five pioneers in the United States to start

bacteria, is introduced.
1962

Abbott launches Glucerna shakes and snack bars, specially formulated

is 20,000 shares for $32 each.

The companys international presence will grow steadily.
1936

Abbott acquires the parenteral products business of Sanofi Pharmaceuticals,

Inc., and also launches several new products, including an improved version

North Chicago, Ill.

1929

The company receives FDA clearance for Norvir, a protease inhibitor for the

business into a new public company, to be named Hospira.

2004

Abbott acquires I-STAT Corp. and TheraSense, Inc. Hospira spins off from
Abbott, becoming one of the largest global specialty pharmaceutical and
medication delivery companies serving the hospital.

25

Six-Year Financial Summary

(dollars in millions except per share data)

Year Ended December 31

2003

2002

2001

2000

1999

1998

Net Sales

$19,680.6

17,684.7

16,285.2

13,745.9

13,177.6

12,512.7

Cost of products sold

$9,473.4

8,506.3

7,748.4

6,238.6

5,977.2

5,406.6

Research and development (1)

$1,733.5

1,561.8

1,577.6

1,351.0

1,194.0

1,228.8

Selling, general and administrative

$5,050.9

3,978.8

3,734.9

2,894.2

2,857.1

2,759.8

Operating earnings (1)

$3,322.5

3,530.1

1,894.0

3,400.6

3,149.4

3,117.6

Interest expense

$188.1

238.9

307.3

113.9

144.7

160.0

Interest income

$(42.0)

(33.7)

(72.6))

(90.7))

(62.9))

(57.4))

Other (income) expense, net

$(558.0)

(348.5))

(223.9))

(439.1))

(329.3

(226.8)

Earnings before taxes (1)

$3,734.4

3,673.4

1,883.1

3,816.4

3,396.9

3,241.9

Taxes on earnings

$981.2

879.7

332.8

1,030.4

951.1

907.5

Net earnings

$2,753.2

2,793.7

1,550.4

2,786.0

2,445.8

2,334.4

Basic earnings per common share

$1.76

1.79

1.00

1.80

1.59

1.52

Diluted earnings per common share

$ 1.75

1.78

.99

1.78

1.57

1.50

Working capital

$2,650.9

2,119.6

492.4

3,078.7

1,903.0

623.9

Long-term investment securities

$406.4

250.8

647.2

638.0

954.8

967.8

Net property and equipment

$6,281.8

5,828.1

5,551.5

4,816.9

4,770.1

4,742.9

Total assets

$26,715.3

24,259.1

23,296.4

15,283.3

14,471.0

13,259.9

Long-term debt

$3,452.3

4,274.0

4,335.5

1,076.4

1,336.8

1,339.7

Shareholders investment

$13,072.3

10,664.6

9,059.4

8,570.9

7,427.6

5,753.6

Return on shareholders investment

%23.2

28.3

17.6

34.8

37.1

43.3

Book value per share

$8.36

6.82

5.83

5.54

4.80

3.76

Gross profit margin

%51.9

51.9

52.4

54.6

54.6

56.8

Research and development to net sales

%8.8

8.8

9.7

9.8

9.1

9.8

Net cash from operating activities

$3,746.4

4,182.9

3,566.8

3,099.6

3,035.1

2,875.3

Capital expenditures

$1,246.7

1,296.4

1,163.7

1,035.9

987.1

993.6

Cash dividends declared per common share

$.98

.94

.84

.76

.68

.60

Common shares outstanding (in thousands)

1,564,518

1,563,068

1,554,530

1,545,934

1,547,020

1,530,672

Number of common shareholders

91,212

94,687

97,760

101,272

106,766

109,864

Number of employees

72,181

71,819

71,426

60,571

57,100

56,510

Sales per employee (in dollars)

$272,656

246,239

228,000

226,939

230,782

221,425

Market price per share high

$47.15

58.00

57.17

56qf

53516

50116

Market price per share low

$33.75

29.80

42.00

29ek

33

32qs

Market price per share close

$46.60

40.00

55.75

48716

36516

49

Summary of Operations:

Financial Position:

Other Statistics:

(1)

26

In 2002, Abbott also recorded a pretax charge of $108 for acquired in-process research and development related to the
acquisitions of the cardiovascular stent business of Biocompatibles International plc, certain cardiovascular stent technology
rights from Medtronic, Inc. and an additional interest of the issued common shares of Hokuriku Seiyaku Co., Ltd. In 2001,
Abbott also recorded a pretax charge of $1,330 for acquired-in-process research and development related to the acquisitions
of the pharmaceutical business of BASF and of Vysis, Inc.

27

Plant Locations

Senior Management

The companys corporate offices are located at 100 Abbott Park Road, Abbott Park,
Illinois 60064-6400. The locations of the companys major plants are listed below.
Abbott Park, Illinois
Abingdon, England
Alameda, California
Altavista, Virginia
Austin, Texas
Barceloneta, Puerto Rico
Beringen, Switzerland
Brockville, Canada
Buenos Aires, Argentina
Campoverde, Italy
Casa Grande, Arizona
Cimangis, Indonesia
Columbus, Ohio
Cootehill/Finisklin, Ireland
Coyoacan, Mexico
Dainabot, Japan
Dallas, Texas
Dartford, England
Delkenheim, Germany
Downers Grove, Illinois
East Windsor, New Jersey
Galway, Ireland
Glen Falls, New York
Goa, India
Granada, Spain
Irving, Texas

Jayuya, Puerto Rico

Johannesburg, South Africa
Kanata, Ontario
Karachi, Pakistan
Katsuyama, Japan
Liestal, Switzerland
Longford, Ireland
Ludwigshafen, Germany
Matsudo, Japan
Mexico City, Mexico
North Chicago, Illinois
Queenborough, England
Rangendingen, Germany
Redwood City, California
Rio de Janeiro, Brazil
Santa Clara, California
Shanghai, China
South Pasadena, California
Sturgis, Michigan
St. Remy, France
Whippany, New Jersey
Witney, England
Worcester, Massachusetts
Wyandotte, Michigan
Zwolle, The Netherlands

Directors
Roxanne S. Austin
Former President and Chief Operating Officer,
DIRECTV, Inc.
El Segundo, Calif.

Addison Barry Rand

Chairman and Chief Executive Officer,
Equitant
Stamford, Conn.

H. Laurance Fuller
Retired Co-Chairman of the Board,
BP Amoco plc
London, United Kingdom

W. Ann Reynolds, Ph.D.

Retired Director, Center for Community
Outreach and Development,
The University of Alabama at Birmingham
Birmingham, Ala.

Richard A. Gonzalez
President and Chief Operating Officer,
Medical Products Group,
Abbott Laboratories
Jack M. Greenberg
Retired Chairman and Chief Executive Officer,
McDonalds Corporation
Oak Brook, Ill.
Jeffrey M. Leiden, M.D., Ph.D.
President and Chief Operating Officer,
Pharmaceutical Products Group,
Chief Scientific Officer,
Abbott Laboratories
The Rt. Hon. Lord Owen CH
Executive Chairman of
Global Natural Energy plc
London, United Kingdom
Boone Powell Jr.
Retired Chairman,
Baylor Health Care System
Dallas, Texas

Richard W. Ashley
Executive Vice President,
Corporate Development

Gary E. McCullough
Senior Vice President,
Ross Products

Richard A. Gonzalez
President and
Chief Operating Officer,
Medical Products Group

Jose M. de Lasa
Executive Vice President,
Secretary and General Counsel

Joseph M. Nemmers
Senior Vice President,
Diagnostics Operations

Thomas C. Freyman
Executive Vice President,
Finance and
Chief Financial Officer

Thomas M.Wascoe
Senior Vice President,
Human Resources

Jeffrey M. Leiden, M.D., Ph.D.

President and
Chief Operating Officer,
Pharmaceutical
Products Group
Chief Scientific Officer

Holger Liepmann
Senior Vice President,
International Operations

Corporate Officers
Catherine V. Babington
Vice President, Investor
Relations and Public Affairs

Edward J. Fiorentino
Vice President and President,
MediSense

Edward L. Michael
Vice President and President,
Molecular Diagnostics

Michael G. Beatrice, Ph.D.

Vice President,
Corporate Regulatory and
Quality Science

Stephen R. Fussell
Vice President, Compensation
and Development

Karen L. Miller
Vice President,
Information Technology

Mark F. Gorman
Vice President, Ross Products,
Medical Nutritionals

Sean E. Murphy
Vice President,
Global Licensing/
New Business Development

Jeffrey R. Binder
Vice President,
Spinal Concepts
Olivier Bohuon
Vice President,
European Operations

Robert B. Hance
Vice President and President,
Vascular Devices
James J. Koziarz, Ph.D.
Vice President, Hep/Retro
R&D and Assay Technical
Support, Diagnostics

Roy S. Roberts
Managing Director,
Reliant Equity Investors
Chicago, Ill.
Retired Group Vice President,
North American Vehicle Sales,
Service and Marketing,
General Motors Corp.
Detroit, Mich.

William E. Brown III, Ph.D.

Vice President,
Diagnostic Assays and
Systems Development

John C. Landgraf
Vice President, Quality
Assurance and Compliance,
Medical Products Group

Douglas C. Bryant
Vice President,
Global Commercial
Operations, Diagnostics

Elaine R. Leavenworth
Vice President,
Government Affairs

William D. Smithburg
Retired Chairman, President and Chief
Executive Officer,
The Quaker Oats Co.
Chicago, Ill.

Thomas F. Chen
Vice President, Pacific, Asia
and Africa Operations

John R.Walter
Retired President and Chief Operating Officer,
AT&T Corp.
Basking Ridge, N.J.;
Former Chairman and
Chief Executive Officer,
R. R. Donnelley & Sons Co.
Chicago, Ill.

Lance B.Wyatt
Senior Vice President,
Global Pharmaceutical
Manufacturing

William G. Dempsey
Senior Vice President,
Pharmaceutical Operations

Charles M. Brock
Vice President, Chief Ethics
and Compliance Officer

Miles D.White
Chairman of the Board
and Chief Executive Officer,
Abbott Laboratories

28

Miles D.White
Chairman of the Board and
Chief Executive Officer

Michael J. Collins
Vice President,
Diagnostic Commercial
Operations, U.S.
Jaime Contreras
Vice President, Diagnostic
Commercial Operations,
Europe, Africa and
the Middle East
Thomas J. Dee
Vice President, Internal Audit

Daniel W. Norbeck, Ph.D.

Vice President, Global
Pharmaceutical Discovery
D. Stafford OKelly
Vice President,
Latin America and Canada
Laura J. Schumacher
Vice President, Secretary and
Deputy General Counsel
AJ J. Shoultz
Vice President, Taxes
Mary T. Szela
Vice President,
Pharmaceutical Products,
Primary Care Operations

Gerald Lema
Vice President, Diagnostic
Commercial Operations,
Asia and Pacific
John M. Leonard, M.D.
Vice President, Global
Pharmaceutical Development

James L. Tyree
Vice President,
Global Licensing/
New Business Development

Greg W. Linder
Vice President and Controller

H. Thomas Watkins*
President, TAP
Pharmaceutical Products Inc.

Richard J. Marasco
Vice President,
Ross Products, Pediatrics

Susan M.Widner
Vice President,
Corporate Marketing

Heather L. Mason
Vice President, Pharmaceutical
Products, Specialty Operations

*Officer of joint venture

P. Loreen Mershimer
Vice President, Hospital
Products Business Sector

29

a
Abbott Laboratories
100 Abbott Park Road, Abbott Park, IL 60064-6400 U.S.A.
(847) 937-6100 www.abbott.com

Published by Abbotts Investor Relations/Public Affairs Division.

Corporate Public Affairs (847) 937-1608 Investor Newsline (847) 937-7300
The ticker symbol for Abbott Laboratories common stock is ABT.
It is listed on the New York, Chicago, Pacific, London and Swiss exchanges.
It is traded on the Boston, Cincinnati and Philadelphia exchanges.
On the cover: Chicago native, Tecela Harris, first experienced symptoms
of rheumatoid arthritis at her senior prom, when pain in her
joints was unbearable. After 18 years of trying numerous medicines
without improvement, Tecela was prescribed Humira. With just
two injections, she experienced a dramatic improvement and has energy
again working full time, spending time with her husband, caring
for her newborn son, and taking walks with her father.
Abbott trademarks and products in-licensed by Abbott
are shown in italics in the text of this Fact Book.
Not all products listed are approved in all countries.
2004, Abbott Laboratories 100M/5/04